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OBJECTIVES: The risk of blindness from glaucoma can be reduced by early detec-
tion and treatment. A domestic large-scale surveillance (Tajimi Study) shows that 
approximately 90% of glaucoma patients of 40 years or older are undiagnosed, and 
initiation of the treatment is delayed. In this study the glaucoma treatment was 
investigated to understand the real-world situation of glaucoma therapy using claim 
data in Japan. METHODS: This was a retrospective cohort study. The data were 
extracted from a Japanese healthcare database (MinaCare Co., Ltd), which contained 
claim data obtained from approximately 2.0 million members of employment-based 
health insurance groups and their dependents. The ICD-10 classification was used 
to identify glaucoma patients. A washout period of 6 months before enrollment was 
set during which there were no records of prescriptions of antiglaucoma drugs or 
glaucoma surgery. Antiglaucoma ophthalmic solutions or surgery for initial treat-
ment, persistence and change in medication were investigated. RESULTS: Out of 
2,074,499 people in the database as of August 2014, we identified 42,470 glaucoma 
patients and the target group who met the wash-out conditions involved 6,333 
patients (male: 3,618; female: 2,715). About 75% of the patients were between 40 to 
69 years old and about 10% were 70 years or older. Regarding the initial treatment, 
most patients started with topical antiglaucoma treatment and only 24 patients 
underwent surgery. The first prescription of antiglaucoma drug included 1 agent 
in 87%, and cases with 2 agents (10%), 3 agents (3%), or more than 3 agents (0.3%) 
were also identified. The most prescribed one was latanoprost (26%) followed by 
tafluprost (17%), and carteolol (10%). CONCLUSIONS: In this study, the initial treat-
ment in most of the patients followed the treatment guidelines. However, lack of 
disease awareness among potential patients and accessibility to early screening and 
diagnosis of glaucoma may exist, and it should be given sufficient consideration.
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OBJECTIVES: Psoriasis (PSO) and psoriatic arthritis (PsA) are immune-mediated 
systemic inflammatory diseases; adalimumab (ADA) and etanercept (ETN) are 
among the most commonly used first-line biologic agents. As per FDA-approved 
dosage and administration, newly initiated PSO patients receive a higher loading 
dose followed by a regular maintenance dose. In clinical practice, however, patients 
may receive higher than recommended (increased) doses even during the mainte-
nance phase of treatment. Given linear pricing of these medications, our objective 
was to determine if the increased dosing schedule increases payer costs and to 
what degree. METHODS: Continuously enrolled adult patients with ≥ 2 outpa-
tient diagnoses of PSO (ICD-9 code: 696.1) or PsA (ICD-9 code: 696.0) were selected 
from the Symphony PTD Claims Database if their first biologic prescription date 
(index date) fell between May 2010 and April 2013. Patients were required to be 
treatment-naïve only to ADA or ETN pre-index. The cost analysis took place over 
12 months post-index. Regular (increased) maintenance dosing was defined as 
ADA 40 mg (> 40 mg) biweekly starting 1 week post-index and ETN 50 mg (> 50 mg) 
weekly starting 3 months post-index. Costs were imputed based on 2015 wholesale 
acquisition costs: $36.4/mg of ADA and $14.9/mg of ETN. RESULTS: 15.0% of 21,234 
ADA patients received increased maintenance doses for PSO and 18.0% of 8,908 for 
PsA. For ETN, the proportion was 31.9% of 16,318 for PSO and 17.0% of 7,647 for PsA. 
Average annual costs for patients receiving an increased vs. regular dose of ADA 
were: PSO: $40,042 vs. $27,319 (P< 0.001), PSA: $43,949 vs. $26,570 (P< 0.001). Average 
annual costs for patients receiving an increased vs. regular dose of ETN were: PSO: 
$46,148 vs. $30,289 (P< 0.001), PSA: $43,816 vs. $30,653 (P< 0.001). CONCLUSIONS: 
A large proportion of patients treated with commonly used biologic agents are 
maintained on increased maintenance doses, significantly increasing payer 
costs.
PSS40
UtilizAtion, PriCe, AnD SPenDing trenDS for flUoroqUinoloneS in tHe 
US meDiCAiD ProgrAm: 1991-2013
Yue X., Guo J.J., Xia Y., Almalki Z.S., Wigle P.R.
University of Cincinnati, Cincinnati, OH, USA
OBJECTIVES: Fluoroquinolones are broad-spectrum antibiotics commonly used in 
the treatment of respiratory tract infections, uncomplicated urinary tract infec-
tions and gastrointestinal infections. This study described and analyzes trends in 
the utilization, spending, and average per-prescription cost of fluoroquinolones 
individually and overall, by the Medicaid programs from 1991 to 2013. METHODS: 
A retrospective, descriptive analysis was performed using the publicly available 
national Summary Files from the Medicaid State Drug Utilization Data maintained 
by the Centers for Medicare & Medicaid Service. Study drugs included ciprofloxa-
cin, gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, and ofloxacin, as well as 
recently withdrawn drugs, grepafloxacin (1999), sparfloxacin (2001), trovafloxacin 
(2001), and gatifloxacin (2006). Annual prescription counts and reimbursement 
amounts were calculated for all fluoroquinolones reimbursed by Medicaid. Average 
per-prescription spending as a proxy for drug price was calculated (estimated) for 
all generic and brand drugs by dividing reimbursement by the number of prescrip-
tion. RESULTS: The total number of fluoroquinolone prescriptions rose 340% from 
1.66 million in1991 to 5.65 million in 2005, and then decreased to 4.21 million in 
2013. Total expenditures on fluoroquinolones increased from $81 million in 1991 to 
$395 million in 2004, and then decreased to $163 million in 2013. The average pre-
prescription price for generic ciprofloxacin was $7.76 in 2013, whereas the price 
OBJECTIVES: Patient-reported outcome (PRO) measures provide patients and clini-
cians with a tool to assess physical, social, and psychological functioning. Individual 
and aggregated data can inform treatment decision making and aid patient 
management. Existing PRO measures for psoriasis typically do not fully capture 
either impact on emotional wellbeing or coping behaviors, including modifiable 
behaviors associated with poor health outcomes and comorbid disease. The aim 
of this study was to develop content for a new PRO for the clinical management of 
psoriasis. METHODS: Patients with chronic plaque psoriasis were identified and 
recruited through two psoriasis-specific clinics. Content was developed and itera-
tively refined through: a) in-depth qualitative, face-to-face interviews (n= 30) using 
a semi-structured interview guide and analyzed using NVivo; b) development of a 
conceptual model and draft items with an expert panel; and c) cognitive debriefing 
of draft items, response scale, and recall period to determine understanding and 
relevance to patients (n= 8). RESULTS: Qualitative analysis revealed seven main 
domains of concern to patients with psoriasis including symptoms and impact on 
negative wellbeing, positive wellbeing, daily activities, illness beliefs, treatment 
beliefs, and coping techniques. A conceptual model is presented, postulating rela-
tionships between concepts identified by patients. An initial bank of 97 items was 
developed; cognitive debriefing revealed that most items were deemed relevant to 
psoriasis experience and could be accurately recalled over a 14-day time period. Six 
items were deleted through redundancy, lack of relevance, or poor understanding. 
A 91-item bank across six sub-scales remained. CONCLUSIONS: The new measure, 
PROMPT, was derived from patient-reported experience and demonstrates initial 
face and content validity in a plaque psoriasis patient population. Further confir-
mation and refinement of items, scales, and scoring structure is planned through 
a large-scale quantitative study using Rasch techniques.
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OBJECTIVES: Many veterinarians are hesitant to recommend cefovecin sodium for 
subcutaneous administration as a first treatment for superficial pyoderma in dogs 
because there is a perception that dog owners will not accept the cost compared to 
less expensive oral medications requiring repeated administration. The objective 
was to assess the impact of weight of the dog using a margin markup pricing method 
on the acceptance by dog owners of cefovecin sodium as a first line treatment 
in appropriate cases. METHODS: Thirty veterinarians in 22 different geographical 
veterinary practices that were members of CAPNA a group of veterinary hospitals 
owned by veterinarians in the US were asked to offer cefovecin sodium as a first 
line treatment for appropriate cases. The date of examination, weight of the dog 
and owner’s acceptance or decline was recorded for a two month period. Owners 
were charged using the weight of the dog multiplied by 1.25 plus a $45 margin 
markup. RESULTS: Of the sample of 683 dogs, 76.28% (n= 521) accepted cefovecin 
sodium as a single subcutaneous administration with an average weight of 32.57 
lbs. and a range of 3-135 lbs. 23.7% (n= 162) declined treatment with an average 
weight of 58.44 lbs. with a range of 10.20-155 lbs. The difference in weights of 25.87 
lbs. was statistically significant (P< 0.0001). The average cost of the accepted cefo-
vecin sodium injection for 32.57 lb dog is $85.71. The average cost of the declined 
cefovecin sodium injection is $118.05.The average cost of the alternative oral medi-
cations for cefpodoxime proxetil administered once daily is $29.96 and cephalexin 
administered twice daily is $5.04. CONCLUSIONS: The dog owners in this study 
accepted treatment with cefovecin sodium as a first line of therapy in 76.2% of the 
cases even though the cost of the onetime treatment was 3 to17 times more than 
oral alternatives.
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OBJECTIVES: To investigate the availability and affordability of antiglaucoma 
medicines in Benin City, Nigeria. METHODS: The study employed retrospective 
and prospective cross sectional design, using data collection forms, WHO/HAI 
data collection format for collection and analysis of medicine prices in public 
and private sectors. The name of the antiglaucoma drugs (branded and generic), 
usual quantities, price prescribed for a month supply to patients, strength, unit 
pack, brand name, lowest priced generic (LPG) were recorded. Physical sighting of 
product was done to confirm availability in that facility. Data was analyzed with 
WakAfford1.0. Medicine Affordability Calculator developed for this study based 
on USD103 (NGN17, 000) minimum wage per month for the least paid government 
worker RESULTS: Thirty-six antiglaucoma medicines were surveyed in the three 
main sectors. The branded products in private pharmacies had 47.22% availabil-
ity, private clinics 38% and public hospital 25%, while the generic medicines had 
25% in private pharmacy, 22.22% in clinics and 19.44% in public hospitals. The 
most affordable branded product in Private pharmacies was acetazolamide tab-
lets (0.16 ± 0.02 days) and Timolol 0.5% eye drop (0.59 ± 0.04 days), while the most 
unaffordable product is Combigan® (brimonidine + timolol) (12.71 ± 0.17days). 
However timolol 0.25% was the most affordable in private clinic while Xalacomb® 
(latanoprost + timolol) was the most unaffordable CONCLUSIONS: The availability 
of antiglaucoma drugs in Benin City is suboptimal and some are unaffordable 
across the different sectors. Government and donor agencies should subsidize 
and make them accessible to patients. Acknowledgement: WakAfford 1.0 afford-
ability calculator developed with BaseCase Interactive donated in an academic 
partnership by BaseCase (Berlin, Germany). Available at www.pub.basecase.com/ 
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B, and stand-alone Part D plan coverage in the 12-months pre- and post-index 
date and have > 1 claim for psoriasis (ICD-9CM code 696.1) in the 12-month pre-
index period. Exclusion criteria included presence of other conditions for which 
these biologics are indicated, or receipt of any biologic in the 12-months pre-
index. Adherence to index biologic was defined as patients with proportion of 
days covered (PDC) > 0.80 during the 12-months post-index. Logistic regression 
analyses were conducted to determine the factors associated with being adher-
ent. RESULTS: Our sample included 2,707 patients newly initiating biologics. 
Overall, mean PDC for any index biologic was 0.61 and only 38% were adherent to 
their index biologic in the 12 months following initiation. Mean PDC and adherence 
rates were similar between physician-administered and self-administered agents, 
but there were several differences by index biologic. Mean PDCs were 0.66 for 
infliximab (N= 318), 0.70 for ustekinumab (N= 280), 0.63 for adalimumab (N= 1084), 
and 0.56 for etanercept (N= 1025). Adherence rates were 49%, 43%, 41%, and 29%, 
respectively. Logistic regression indicated that older age, and female gender 
were associated with poor adherence. Index biologic was also a significant factor 
associated with being adherent. CONCLUSIONS: Adherence with biologic treat-
ment for psoriasis is poor in the Medicare population with rates < 50% across all 
biologics.
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OBJECTIVES: There is a plethora of interventions for the treatment of overactive 
bladder syndrome, including a course of supervised pelvic floor muscle training, 
behavioral therapy, anticholinergic medication, sacral nerve stimulation, and more 
recently, botulinum toxin type A (BoNT-A) and beta-3-adrenergic agonists. Though 
there is a large and diverse range of treatment options, there is little information 
of which of them is the most clinically effective. This is largely because trials often 
compare interventions with a placebo or with interventions of the same class; and 
so there are a limited number of trials that compare interventions of different 
classes, and thus different approaches on a head-to-head basis. METHODS: We 
searched Medline, EMBASE, Cochrane Incontinence Group Specialized Register, 
and all relevant references for randomized controlled trials evaluating interven-
tions for OAB through to October 2014. Using Bayesian Markov Chain Monte Carlo 
(MCMC) methods, we applied a hierarchical network meta-analysis that accounts 
for the exchangeability of treatment effects between different modes of admin-
istration (e.g. extended and immediate release), between treatments within the 
same class (e.g. anticholinergics) and the residual between-study heterogeneity. 
We further adjusted for differences in baseline severity of the patient population, 
as different interventions are used at varying times in the treatment pathway. 
The primary outcomes of interest were mean change from baseline for voiding, 
urgency, and incontinence episodes. RESULTS: Preliminary results show that for 
voiding and urgency episodes, BoNT-A 200u was the most effective intervention. 
BoNT-A 300u was the most effective intervention for reducing incontinence epi-
sodes. CONCLUSIONS: BoNT-A was found to be the most effective intervention for 
reducing symptoms of OAB. Accounting for the exchangeability between different 
modes of administration and treatments within in the same class sufficiently 
increases the precision in the treatment effect estimates but maintains the inter-
pretability of the individual and diverse range of treatment options.
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OBJECTIVES: LUTS associated with BPH (LUTS/BPH) in men may present as a 
combination of voiding, storage and post-micturition symptoms. UK prescribers 
have proposed two areas of improvement to current care: first, acknowledging 
that α -blocker monotherapy may not address bothersome storage symptoms; and 
second, building confidence in primary care to prescribe drug combinations for 
mixed symptoms. We built a model to evaluate the potential budget savings from 
implementing these treatment pathway changes. METHODS: A model was built 
in Microsoft® Excel to depict a simplified LUTS care pathway, aligned with current 
clinical practice and NICE treatment recommendations in a hypothetical cohort 
of 10,000 men with LUTS/BPH who have moderate-to-severe storage and voiding 
symptoms. The budget impact of a proposed pathway redesign was calculated, 
which could adjust the number of men diagnosed and managed in primary care. 
Men could receive a range of treatment options, and if symptoms persisted, could 
ultimately be recommended for surgery. RESULTS: The model estimated several 
annual cost savings: –£2,964,169 by increasing the proportion of men diagnosed 
in primary rather than secondary care from 30% to 40%; –£1,623,701 by increasing 
the proportion of men receiving initial LUTS treatment in primary rather than 
secondary care from 50% to 60%; and –£4,114,738 by increasing the proportion of 
men receiving combination rather than monotherapy from 6% to 20%. A combi-
nation of all proposed changes resulted in a saving of –£8,208,061. Varying drug 
choice or cost were shown to have minimal financial impact. CONCLUSIONS: The 
pathway redesign indicates substantial savings. Specifically, increasing primary 
care diagnosis and treatment of LUTS/BPH symptoms would avoid referral costs 
and potentially delay surgery, while increasing general practitioner confidence 
per-prescription of branded (Cipro) ciprofloxacin was $149.34. The sharp decrease 
in the utilization of Trovan can be explained by the withdrawal from the market 
in 2001 because of risk of liver failure. CONCLUSIONS: Increased expenditures 
for fluoroquinolones paralleled with increased utilization. Generic drug utiliza-
tion increased dramatically after brand-name patent expiration. Fluoroquinolone 
drug utilization might be also associated with its safety profile and related disease 
treatment guidelines.
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OBJECTIVES: Obesity is associated with increased risk of soft tissue infection and 
clinical failure; however, the association between obesity and longer-term clinical 
outcomes in ABSSSI patients is not well-studied. This study compared hospital read-
mission rates between obese and non-obese ABSSSI patients. METHODS: Adults 
(> 18 years) hospitalized with ≥ 1 primary ABSSSI diagnosis were selected from the 
Cerner HealthFacts electronic medical records database (2009-2013). The first pri-
mary ABSSSI inpatient admission was defined as the index admission. Patients 
were categorized into obese (BMI> 30) and non-obese cohorts at the index admis-
sion. Proportions of patients with all-cause and ABSSSI-related readmission to the 
same hospital within 30 days were compared between the cohorts descriptively 
(in subgroups defined by gender, age, and causative pathogen) and using multi-
variable logistic regression adjusting for hospital size, demographics, insurance 
type, causative pathogen, and important comorbidities. RESULTS: 5,823 obese and 
5,882 non-obese patients were identified. Fewer obese patients were male (47.8% vs 
55.8%), ≥ 65 years old (28.2% vs 34.3%), and admitted to teaching hospitals (70.7% vs 
73.4%). Same-hospital 30-day readmission rates were higher for obese patients for 
both all-cause (12.9% vs 11.8%, p= 0.085) and ABSSSI-related (5.3% vs 4.0% p= 0.0019) 
readmissions. ABSSSI-related readmission rates remained significantly higher for 
obese patients among males (5.1% vs 3.8%, p= 0.0086), younger patients (age < 65 
years, 5.0% vs 3.6%, p= 0.0026), and those not infected with methicillin-resistant 
staphylococcus aureus (5.3% vs 4.2%, p= 0.0049). In multivariable regressions, obese 
patients had higher odds of 30-day readmission for all-cause readmissions (obese 
vs non-obese: OR= 1.10, p= 0.0944) and significantly higher odds of ABSSSI-related 
readmissions (OR= 1.28, p= 0.0073). CONCLUSIONS: Obese ABSSSI patients experi-
enced higher rates of same-hospital ABSSSI-related readmission compared with 
non-obese patients. The association persisted in male, age < 65, and non-MRSA sub-
groups and remained significant after adjustment for confounding. Further studies 
are warranted to estimate total readmission rates, which may be underestimated 
by same-hospital readmission rates.
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OBJECTIVES: Identify and analyze the level of scientific production in the oral 
health field worldwide, by applying quantitative assessment counting meth-
ods and bibliometric analysis. METHODS: The review was realized using the 
Scopus database, given its greater coverage according to The Academic Database 
Assessment Tool. The results were analyzed through production, dissemination, 
collaboration and bibliometric indicators, which considered the trends in publica-
tion, authors, document type, workspace, magazines, country, number of citations, 
impact factor, h-index and dissemination network. A descriptive analysis was 
performed from the public policy context in oral health, in addition to the estima-
tion of trends and state of the art investigation. RESULTS: 1.727 scientific articles 
were found through searching terms associated with “oral health” AND “public 
health” AND “public policy”. The annual growth function provided an increased 
trend since 2000. The United States, Brazil and the United Kingdom were the 
countries with the highest impact and development in the oral health field, pro-
viding 40.7% of the total references found. The production is allied especially to 
universities and research groups, mainly the University of Sao Paulo, University of 
Adelaide and University of North Carolina at Chapel Hill. The areas of knowledge 
with the greater incidence were: medicine (44.1%), Dentistry (39%) and social sci-
ences (4.8%). The search for oral health had an index h: 46. CONCLUSIONS: The 
scientific production in oral health topics shows increasing development and 
institutional affluence. It is expected that the oral health problems analyzed would 
have solutions and support from the government of the region and the allocation 
of resources for health.
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OBJECTIVES: Biologics have provided major advances in the treatment of 
plaque psoriasis. Little is known regarding adherence to biologics and factors 
associated with adherence in the Medicare population. This study is the first 
to examine adherence among Medicare patients with psoriasis newly initiating 
biologics. METHODS: The 2009 to 2012 Medicare 100% files were used to iden-
tify patients who received infliximab, ustekinumab, adalimumab, or etanercept 
between 1/1/2010 and 12/31/2011. The date of first biologic prescription defined 
the index date. Patients were required to have fee-for-service Medicare Parts A, 
